Caplacizumab
Other Antithrombotic Agents
Sold as Cablivi
- Drug class
- Other Antithrombotic Agents
- Availability
- See label
- Markets covered
- 2
- Products on record
- 2
Overview
Caplacizumab is an active pharmaceutical ingredient in the Other Antithrombotic Agents group (B01AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| EU European Union | EMA | 1 | May 27, 2026 |
| GB United Kingdom | MHRA | 1 | April 24, 2026 |
EUEuropean Union· EMA
1 product
Uses
Cablivi is indicated for the treatment of adults and adolescents of 12 years of age and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
How to take
GBUnited Kingdom· MHRA
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Caplacizumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]European Medicines Agency · EMEA/H/C/004426 · revised May 27, 2026
- [2]MHRA (UK) · PLGB044250888 · revised April 24, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.